Cargando…

Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma

Glioblastoma (GBM) patients exhibit high mortality and recurrence rates despite multimodal therapy. Small nucleolar RNA host genes (SNHGs) are a group of long noncoding RNAs that perform a wide range of biological functions. We aimed to reveal the role of SNHGs in GBM subtypes, cell infiltration int...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yang, Gao, Zijie, Xu, Jianye, Wang, Huizhi, Guo, Qindong, Xue, Hao, Zhao, Rongrong, Guo, Xing, Li, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493242/
https://www.ncbi.nlm.nih.gov/pubmed/36159816
http://dx.doi.org/10.3389/fimmu.2022.986615
_version_ 1784793660441755648
author Fan, Yang
Gao, Zijie
Xu, Jianye
Wang, Huizhi
Guo, Qindong
Xue, Hao
Zhao, Rongrong
Guo, Xing
Li, Gang
author_facet Fan, Yang
Gao, Zijie
Xu, Jianye
Wang, Huizhi
Guo, Qindong
Xue, Hao
Zhao, Rongrong
Guo, Xing
Li, Gang
author_sort Fan, Yang
collection PubMed
description Glioblastoma (GBM) patients exhibit high mortality and recurrence rates despite multimodal therapy. Small nucleolar RNA host genes (SNHGs) are a group of long noncoding RNAs that perform a wide range of biological functions. We aimed to reveal the role of SNHGs in GBM subtypes, cell infiltration into the tumor microenvironment (TME), and stemness characteristics. SNHG interaction patterns were determined based on 25 SNHGs and systematically correlated with GBM subtypes, TME and stemness characteristics. The SNHG interaction score (SNHGscore) model was generated to quantify SNHG interaction patterns. The high SNHGscore group was characterized by a poor prognosis, the mesenchymal (MES) subtype, the infiltration of suppressive immune cells and a differentiated phenotype. Further analysis indicated that high SNHGscore was associated with a weaker response to anti-PD-1/L1 immunotherapy. Tumor cells with high SNHG scores were more sensitive to drugs targeting the EGFR and ERK-MAPK signaling pathways. Finally, we assessed SNHG interaction patterns in multiple cancers to verify their universality. This is a novel and comprehensive study that provides targeted therapeutic strategies based on SNHG interactions. Our work highlights the crosstalk and potential clinical utility of SNHG interactions in cancer therapy.
format Online
Article
Text
id pubmed-9493242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94932422022-09-23 Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma Fan, Yang Gao, Zijie Xu, Jianye Wang, Huizhi Guo, Qindong Xue, Hao Zhao, Rongrong Guo, Xing Li, Gang Front Immunol Immunology Glioblastoma (GBM) patients exhibit high mortality and recurrence rates despite multimodal therapy. Small nucleolar RNA host genes (SNHGs) are a group of long noncoding RNAs that perform a wide range of biological functions. We aimed to reveal the role of SNHGs in GBM subtypes, cell infiltration into the tumor microenvironment (TME), and stemness characteristics. SNHG interaction patterns were determined based on 25 SNHGs and systematically correlated with GBM subtypes, TME and stemness characteristics. The SNHG interaction score (SNHGscore) model was generated to quantify SNHG interaction patterns. The high SNHGscore group was characterized by a poor prognosis, the mesenchymal (MES) subtype, the infiltration of suppressive immune cells and a differentiated phenotype. Further analysis indicated that high SNHGscore was associated with a weaker response to anti-PD-1/L1 immunotherapy. Tumor cells with high SNHG scores were more sensitive to drugs targeting the EGFR and ERK-MAPK signaling pathways. Finally, we assessed SNHG interaction patterns in multiple cancers to verify their universality. This is a novel and comprehensive study that provides targeted therapeutic strategies based on SNHG interactions. Our work highlights the crosstalk and potential clinical utility of SNHG interactions in cancer therapy. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9493242/ /pubmed/36159816 http://dx.doi.org/10.3389/fimmu.2022.986615 Text en Copyright © 2022 Fan, Gao, Xu, Wang, Guo, Xue, Zhao, Guo and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Fan, Yang
Gao, Zijie
Xu, Jianye
Wang, Huizhi
Guo, Qindong
Xue, Hao
Zhao, Rongrong
Guo, Xing
Li, Gang
Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma
title Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma
title_full Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma
title_fullStr Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma
title_full_unstemmed Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma
title_short Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma
title_sort identification and validation of snhg gene signature to predict malignant behaviors and therapeutic responses in glioblastoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493242/
https://www.ncbi.nlm.nih.gov/pubmed/36159816
http://dx.doi.org/10.3389/fimmu.2022.986615
work_keys_str_mv AT fanyang identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma
AT gaozijie identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma
AT xujianye identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma
AT wanghuizhi identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma
AT guoqindong identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma
AT xuehao identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma
AT zhaorongrong identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma
AT guoxing identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma
AT ligang identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma